Epilepsy

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Common stock, Therapy, Epilepsy, Employment, Compensated emancipation, Medication

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 47,400 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • These stock option grants have an exercise price of $8.68 per share, which is equal to the closing price of the Common Stock on April 4, 2024 (date of grant for such stock options).
  • These stock options were granted as inducements material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.

Pyros Pharmaceuticals Announces VIGPODER™ (vigabatrin) is Now Available

Retrieved on: 
Monday, April 1, 2024
Parenting, FDA, Neurology, Children, Biotechnology, Family, Health, Consumer, Pharmaceutical, Diagnosis, Epilepsy, Medication, USP, Pyros, Caregiver, Patient, Epileptic spasms, Child, Vigabatrin, Spasm, Safety, Multimedia, Central Time, Pharmaceutical industry

Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that VIGPODER™ (vigabatrin) for oral solution, USP, a treatment for appropriate patients with infantile spasms (IS), is now available.

Key Points: 
  • Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that VIGPODER™ (vigabatrin) for oral solution, USP, a treatment for appropriate patients with infantile spasms (IS), is now available.
  • As a therapeutically equivalent product, VIGPODER™ is anticipated to offer the same safety and efficacy profile as SABRIL® (vigabatrin) for oral solution.
  • Additionally, Pyros Total Care™, the Company’s personalized comprehensive support program, is available to assist families throughout the treatment journey.
  • "The launch of VIGPODER™ and the Pyros Total Care™ program underscores our dedication to supporting families facing the challenges of infantile spasms," stated Michael Smith, Chief Executive Officer at Pyros.

Texas Original Announces Opening of Sugar Land Location, Launches New RSO Gummies

Retrieved on: 
Wednesday, March 27, 2024
Vitamins, Supplements, Tobacco, Cannabis, Alternative Medicine, General Health, Pharmaceutical, Health, Retail, Natural Resources, Oncology, Dark, Epilepsy, Spasticity, Cannabinoid, RSO, Patient, Flavonoid, Cancer, Terpene, Protein, Originality, THC, Physician, PTSD, Diabetic neuropathy, Medicinal plants

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.
  • Texas Original also announced the launch of its new Pineapple Gummies, a 20 mg THC-only product made with Rick Simpson Oil (RSO).
  • Alongside the company’s recently launched Dark Chocolate Bites and RSO Tincture, Texas Original’s Pineapple Gummies are among the first medical cannabis products in the state—and the first gummy product—to incorporate RSO.
  • Texans can obtain medical cannabis prescriptions through online clinics or local physicians registered with the Compassionate Use Registry of Texas.

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Neurology, Legal, Finance, General Health, Pharmaceutical, PGR, Plasma, Medication, Patent, Patient, Ganaxolone, PTAB, IPR, Marinus, Pharmacology, Inter partes review, Patent office, Therapy, Epilepsy, Status epilepticus, Pharmaceutical industry

This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).

Key Points: 
  • This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).
  • “Over the past two decades, Marinus has invested more than $100 million into our ganaxolone development programs in SE,” stated Dr. Scott Braunstein, Chairman and CEO of Marinus.
  • We believe this Ovid challenge is without merit and is an unfortunate distraction to the important work we do at Marinus.
  • In response to Marinus’ request for PGR, Ovid abandoned 23 of the 31 claims in its patent.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Telestream Introduces AI-Powered Tools for Rapid Content Delivery at NAB Show 2024

Retrieved on: 
Tuesday, March 19, 2024
Technology, Social Media, Entertainment, Mobile Entertainment, Media, General Entertainment, Artificial Intelligence, Telecommunications, Software, Digital Marketing, Communications, Internet, TV and Radio, Licensing (Entertainment), Photon, Automation, Web browser, DIVA, QC, Elasticsearch, Organization, MAM, OTT, SRT, Quality control, NAB, Social media, Artificial intelligence, AI, GLIM, Dolby Vision, IMF, Interoperable Master Format, Telestream, Epilepsy, ST 2110, Safety, Language, Metadata, NDI, Video game

This new flexibility not only accelerates content delivery but also empowers companies to capture and monetize additional content, unhindered by the physical constraints of onsite infrastructure.

Key Points: 
  • This new flexibility not only accelerates content delivery but also empowers companies to capture and monetize additional content, unhindered by the physical constraints of onsite infrastructure.
  • In today's multi-platform media environment, the rapid delivery of high-quality content across various platforms is a necessity.
  • Intelligent Quality Control (QC): Telestream's AI-driven QC tools automate the process of ensuring consistent content quality across large volumes of media.
  • For more information about Telestream products and services at NAB Show 2024, please visit: www.telestream.net/nab .

TSC Alliance® Announces 23rd Annual Step Forward to Cure TSC®

Retrieved on: 
Monday, April 1, 2024
TSC, Epilepsy, Step Forward, Brain, Disease, Seizure, Neoplasm, Research, Tuber, Quality of life, Life, Skin, Heart, Spectrum, DSM-IV codes, Fisher

SILVER SPRING, Md., April 1, 2024 /PRNewswire/ -- As part of its 50th anniversary activities, the TSC Alliance® will present its 23rd Annual Step Forward to Cure TSC® event series, which will take place between April 13 and May 19. Nobelpharma is the 2024 Title Sponsor.

Key Points: 
  • SILVER SPRING, Md., April 1, 2024 /PRNewswire/ -- As part of its 50th anniversary activities, the TSC Alliance ® will present its 23rd Annual Step Forward to Cure TSC ® event series, which will take place between April 13 and May 19.
  • Proceeds will benefit the TSC Alliance's research efforts to find new treatments for tuberous sclerosis complex (TSC) and to offer an array of support programs and services.
  • "Each year, our Step Forward to Cure TSC events offer easy opportunities to support our cause," explained Kari Luther Rosbeck, TSC Alliance President & CEO.
  • "The TSC Alliance's Step Forward to Cure TSC campaign offers a fun and healthy way for anyone to have a positive impact on achieving that goal.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Insights into the Future of Neurology Devices: Exploring the Global Market Report by BCC Research

Retrieved on: 
Thursday, March 28, 2024
Epilepsy, Organization, MRI, Prevalence, Brain, Multiple sclerosis, Data analysis, Neuro, Alzheimer's disease, Nervous system, Patient, Radiosurgery, Research, Spinal cord stimulator, Electrode, Parkinson's disease, Low back pain, Investment, DSM-IV codes, Neurosurgery, Population growth, Ageing, Medical imaging

BOSTON, March 28, 2024 /PRNewswire/ -- According to the latest research study, the demand for Neurology Devices: Global Markets expected to grow from $23.7 billion in 2023 to $31.7 billion by the end of 2028 at a compound annual growth rate (CAGR) of  6.0% from 2023 through 2028.

Key Points: 
  • Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions.
  • The report looks at things like how much these devices are used, where they're used, and how the market for them is growing.
  • This report thoroughly examines the global market for neurology devices, categorizing it by product type and region.
  • Non-surgeons are increasingly performing spinal cord stimulation procedures instead of neurosurgeons due to the rising global burden of low back pain.

World's first field-installed, clinically approved parallel transmit 7T MRI scanner resides at Auburn University

Retrieved on: 
Tuesday, March 26, 2024
College, Epilepsy, Physics, Friends, Brain, MRI, Cell, Terra, Multiple sclerosis, Magnetic resonance imaging, Homeostasis, Biomedical Research, Post-traumatic stress disorder, Intelligence, Patient, Physiology, Physician, Education, DSM-IV codes, Tay–Sachs disease, Research, Gold, History, Economic development, Biomarker, Auburn University, Light, Sodium, Computer engineering, Electricity, Parkinson's disease, Cognition, Veterinary medicine, Liberal arts education, Multimedia, Disorder, Emotion, Engineering, Food, Medical imaging

Additionally, with dedicated radiofrequency sodium imaging coils and parallel transmit technology, the scanner offers expanded imaging capabilities.

Key Points: 
  • Additionally, with dedicated radiofrequency sodium imaging coils and parallel transmit technology, the scanner offers expanded imaging capabilities.
  • These areas represent an intersection between the needs of the MRI research community, particularly in 7T imaging, and existing expertise and strengths of Auburn University.
  • A stark difference between the old and new 7T scanners involve parallel transmit technology and sodium imaging capability.
  • "If it wasn't for them, we wouldn't have the 7T, and we are indebted to them for their dedication and commitment to Auburn.